Abstract
Progress in the treatment of rheumatoid arthritis (RA) has changed the concept of management goals for the disease. In this situation, it is important to accurately diagnose RA in persons with arthralgia in Ningen Dock. The 2010 RA classification criteria proposed by the American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) are used for this purpose. In accordance with the recommendation in the criteria, citrullinated peptide antibody (ACPA) is measured for secondary testing in Ningen Dock. In addition, we should keep in mind adverse reactions of methotrexate or biological agents, risk factors for cerebrovascular diseases, malignancy and osteoporosis when patients with RA in remission visit Ningen Dock.
